News

HCC Q2 Results

Indigo Paints Q2 Results

ABB India Q3 CY25 Earnings

NHPC Q2 Results

Mankind Pharma Q2 Results

GSK Pharma Q2 Results

Kirloskar Ferrous Industries Q2 Results

GMM Pfaudler Q2 Results

Crompton Greaves Q2 Results

Bajaj Housing Finance Q2 Results

JK Lakshmi Cement Q2 Results

Hind Rectifiers Q2 Results

NCC Q2 Results

STL Q2 Results

Net Profit At ₹4 Cr Vs Loss Of ₹14 Cr (YoY)

Revenue down 4% At ₹1,034 Cr Vs ₹1,074 Cr (YoY)

EBITDA up 10.3% At ₹129 Cr Vs ₹117 Cr (YoY)

Margin At 12.5% Vs 10.9% (YoY)

JBM Auto Q2 Results

Net Profit down 44.2% At Rs 25 Cr Vs Rs 44.8 Cr (YoY)

Revenue up 11.2% At Rs 315.2 Cr Vs Rs 283.4 Cr (YoY)

EBITDA up 8.5% At Rs 41 Cr Vs Rs 37.8 Cr (YoY)

Margin At 13% Vs 13.3% (YoY)

Net Profit Flat At Rs 90 Cr (YoY)

Revenue up 4% At Rs 1,342.5 Cr Vs Rs 1,292.4 Cr (YoY)

EBITDA up 3.3% At Rs 194.5 Cr Vs Rs 188 Cr (YoY)

Margin Flat At 14.5% (YoY)

Abbott India Ltd on Thursday (November 6) reported a 16% year-on-year rise in net profit to ₹415.3 crore for the quarter ended September 2025, compared with ₹359 crore in the same period last year, driven by steady revenue growth and stronger operating margins.

Revenue from operations grew 7.7% to ₹1,757 crore, up from ₹1,633 crore a year earlier, the company said in its exchange filing. The healthcare major’s EBITDA rose 14.5% to ₹502.6 crore from ₹439 crore in the corresponding quarter last year. Operating performance improved, with EBITDA margin expanding to 28.6%, compared with 26.9% in the same quarter last year.

here

Shares of Cholamandalam Investment & Finance Company fell as much as 5% on Thursday, November 6, in response to its September quarter results.

Cholamandalam’s asset quality deteriorated on a sequential basis with gross NPA at 4.57% from 4.29% in June, while Net NPA also deteriorated to 3.07% to 2.86% in the previous quarter. These figures are as per the RBI asset classification norms. Provision Coverage Ratio (PCR) for the quarter stood at 33.88% from 34.41% in June.

here

Net Profit up 13.9% At Rs 84.6 Cr Vs Rs 74.3 Cr (YoY)

Revenue up 19% At Rs 1,535 Cr Vs Rs 1,290 Cr (YoY)

EBITDA up 21.4% At Rs 177.9 Cr Vs Rs 146.5 Cr (YoY)

Margin At 11.6% Vs 11.4% (YoY)

Net Profit At Rs 553 Crore Vs Loss Of Rs 443 Crore (YoY)

One-Time Gain At Rs 142 Crore Vs Loss Of Rs 8 Crore (YoY)

Revenue Up 8.4% At 12019 Crore Vs 11 090 Crore (YoY)

EBITDA Up 40% At 2,205 Crore Vs 1,575 Crore (YoY)

Margin At 18.3% Vs 14.2% (YoY)

UPL Raises FY26 EBITDA Guidance To 12-16% Vs Earlier 10-14%

Revenue Growth Guidance Unchanged, Growth Seen At 4-8%

Net Profit up 23.8% At Rs 21.8 Cr Vs Rs 17.6 Cr (YoY)

Revenue down 3.1% At Rs 278.6 Cr Vs Rs 287.5 Cr (YoY)

EBITDA up 26.1% At Rs 39 Cr Vs Rs 30.95 Cr (YoY)

Margin At 14% Vs 10.8% (YoY)

Zydus Lifesciences Ltd on Tuesday reported a robust second-quarter performance for FY26, with consolidated net profit rising 39% year-on-year to ₹1,259 crore, compared with ₹911 crore in the same period last year.

The growth was supported by healthy business momentum across geographies and a sharp rise in forex gains.

The company recorded a foreign exchange gain of ₹414 crore, compared with ₹45 crore in the previous year.

here

Chola Invst Q2

Net Profit At Rs 1,155 Cr Vs CNBC-TV18 Poll Of Rs 1,170 Cr

NII At Rs 3,378 Cr Vs CNBC-TV18 Poll Of Rs 3,359 Cr

PPoP At Rs 2,458 Cr Vs CNBC-TV18 Poll Of Rs 2,482 Cr

Provisions At Rs 897 Cr Vs CNBC-TV18 Poll Of Rs 907 Cr

Net Profit up 20%  At Rs 1,155 Cr Vs Rs 963 Cr (YoY)

NII up 24.5%  At Rs 3,378 Cr Vs Rs 2,713 Cr (YoY)

Gross NPA At 5.57% Vs 4.29% (QoQ)

Board Approves Stock Split In The Ratio Of 1:5

Net Profit down 14%  At Rs 30.4 Cr Vs Rs 35.3 Cr (YoY)

Revenue up 10%  At Rs 219 Cr Vs Rs 199 Cr (YoY)

EBITDA down 2.5%  At Rs 58 Cr Vs Rs 59.4 Cr (YoY)

Margin At 26.4% Vs 29.8% (YoY)

Net Profit down 5.6% At Rs 55.4 Cr Vs Rs 58.7 Cr (YoY)

Revenue up 2.8%  At Rs 244.6 Cr Vs Rs 238 Cr (YoY)

EBITDA down 2.8%  At Rs 87.1 Cr Vs Rs 89.5 Cr (YoY)

Margin At 35.60% Vs 37.62% (YoY)

Net Profit up 2.7% At Rs 33.4 Cr Vs Rs 32.5 Cr (YoY)

Revenue up 17.8%  At Rs 968 Cr Vs Rs 822 Cr (YoY)

EBITDA up 10.3%  At Rs 85.60 Cr Vs Rs 77.60 Cr (YoY)

Margin At 8.84% Vs 9.44% (YoY)

Net profit (GU)16% at ₹415.3 crore vs ₹359 crore (YoY)

Revenue (GU)7.7% at ₹1,757 crore vs ₹1,633 crore (YoY)

EBITDA (GU)14.5% at ₹502.6 crore vs ₹439 crore (YoY)

Margin at 28.6% vs 26.9% (YoY)

Net loss at ₹64.4 crore vs loss of ₹54.2 crore (YoY)

Revenue (RD)12% at ₹494.8 crore vs ₹562.6 crore (YoY)

EBITDA (RD)7% at ₹14.8 crore vs ₹16 crore (YoY)

Margin at 3% vs 2.8% (YoY)NewsLive TVMarketPopular CategoriesCalculatorsTrending NowLet's Connect with CNBCTV 18Network 18 Group :©TV18 Broadcast Limited. All rights reserved.